EA200901201A1 - Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы - Google Patents

Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы

Info

Publication number
EA200901201A1
EA200901201A1 EA200901201A EA200901201A EA200901201A1 EA 200901201 A1 EA200901201 A1 EA 200901201A1 EA 200901201 A EA200901201 A EA 200901201A EA 200901201 A EA200901201 A EA 200901201A EA 200901201 A1 EA200901201 A1 EA 200901201A1
Authority
EA
Eurasian Patent Office
Prior art keywords
asthma
treatment
prevention
dipropionate
formotherol
Prior art date
Application number
EA200901201A
Other languages
English (en)
Other versions
EA018589B1 (ru
Inventor
Паоло Кьези
Ивано Ронделли
Даниэла Ачерби
Джанлуиджи Поли
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200901201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of EA200901201A1 publication Critical patent/EA200901201A1/ru
Publication of EA018589B1 publication Critical patent/EA018589B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к применению композиции, содержащей фиксированную комбинацию (а) формотерола, его фармацевтически приемлемых соли или сольвата либо сольвата такой соли и (б) дипропионата беклометазона, для изготовления лекарственного средства для применения в предотвращении и/или лечении обострения астмы, интермиттирующей астмы и/или приступов при хронической астме во время поддерживающей терапии астмы той же композицией для симптоматического облегчения при необходимости.
EA200901201A 2007-04-19 2008-04-16 Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы EA018589B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (en) 2007-04-19 2007-04-19 Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
PCT/EP2008/003012 WO2008128685A1 (en) 2007-04-19 2008-04-16 Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma

Publications (2)

Publication Number Publication Date
EA200901201A1 true EA200901201A1 (ru) 2010-04-30
EA018589B1 EA018589B1 (ru) 2013-09-30

Family

ID=38458097

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901201A EA018589B1 (ru) 2007-04-19 2008-04-16 Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы

Country Status (30)

Country Link
US (1) US20080261932A1 (ru)
EP (3) EP1982709A1 (ru)
JP (2) JP5492072B2 (ru)
KR (3) KR101668203B1 (ru)
CN (1) CN101657191B (ru)
AU (1) AU2008241045C1 (ru)
BR (1) BRPI0809800A2 (ru)
CA (1) CA2684539A1 (ru)
CO (1) CO6220945A2 (ru)
CY (1) CY1117568T1 (ru)
DK (1) DK2146704T3 (ru)
EA (1) EA018589B1 (ru)
ES (2) ES2740103T3 (ru)
GE (1) GEP20145999B (ru)
HK (1) HK1137357A1 (ru)
HR (1) HRP20160588T1 (ru)
HU (1) HUE029263T2 (ru)
IL (1) IL201632A (ru)
MA (1) MA31315B1 (ru)
ME (1) ME00945B (ru)
MX (1) MX2009010851A (ru)
MY (1) MY169579A (ru)
NZ (1) NZ580526A (ru)
PL (2) PL3034073T3 (ru)
RS (1) RS54874B1 (ru)
SI (1) SI2146704T1 (ru)
TN (1) TN2009000390A1 (ru)
TR (1) TR201909857T4 (ru)
UA (1) UA100237C2 (ru)
WO (1) WO2008128685A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
BR112012007484A2 (pt) * 2009-10-02 2020-06-09 Chiesi Farm Spa formulações aerossóis farmacêuticas de formoterol e dipropionato de beclometasona
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
ES2683254T3 (es) * 2012-01-25 2018-09-25 Chiesi Farmaceutici S.P.A. Formulación en polvo seca que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
ES2841649T5 (es) * 2016-09-19 2024-04-24 Mexichem Fluor Sa De Cv Composición farmacéutica
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2024097413A1 (en) * 2022-11-03 2024-05-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
CZ303833B6 (cs) 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
MXPA04008372A (es) 2002-03-01 2004-11-26 Chiesi Farma Spa Formulacion superfina de formoterol.
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Also Published As

Publication number Publication date
ES2740103T3 (es) 2020-02-05
BRPI0809800A2 (pt) 2014-10-07
MA31315B1 (fr) 2010-04-01
DK2146704T3 (en) 2016-05-23
MY169579A (en) 2019-04-22
CN101657191B (zh) 2014-06-11
JP5492072B2 (ja) 2014-05-14
WO2008128685A1 (en) 2008-10-30
EA018589B1 (ru) 2013-09-30
KR101668203B1 (ko) 2016-10-20
HUE029263T2 (en) 2017-02-28
NZ580526A (en) 2012-07-27
AU2008241045C1 (en) 2023-06-15
KR20150082699A (ko) 2015-07-15
PL3034073T3 (pl) 2019-11-29
CA2684539A1 (en) 2008-10-30
TN2009000390A1 (en) 2010-12-31
TR201909857T4 (tr) 2019-07-22
US20080261932A1 (en) 2008-10-23
IL201632A (en) 2016-09-29
AU2008241045A1 (en) 2008-10-30
GEP20145999B (en) 2014-01-10
CO6220945A2 (es) 2010-11-19
HK1137357A1 (en) 2010-07-30
KR101621676B1 (ko) 2016-05-16
CY1117568T1 (el) 2017-04-26
AU2008241045B2 (en) 2013-06-20
PL2146704T3 (pl) 2016-09-30
JP2010524873A (ja) 2010-07-22
CN101657191A (zh) 2010-02-24
SI2146704T1 (sl) 2016-05-31
MX2009010851A (es) 2009-11-05
RS54874B1 (sr) 2016-10-31
KR20100014408A (ko) 2010-02-10
EP2146704B1 (en) 2016-03-23
UA100237C2 (ru) 2012-12-10
EP3034073B1 (en) 2019-06-12
EP2146704A1 (en) 2010-01-27
KR20150038618A (ko) 2015-04-08
ME00945B (me) 2012-06-20
JP2014005312A (ja) 2014-01-16
IL201632A0 (en) 2010-05-31
EP3034073A1 (en) 2016-06-22
ES2568497T3 (es) 2016-04-29
HRP20160588T1 (hr) 2016-07-01
EP1982709A1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
EA200901201A1 (ru) Применение композиции, содержащей формотерол и дипропионат беклометазона, для предотвращения и/или лечения обострения астмы
EA200801997A1 (ru) Новые соединения
HK1133787A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SV2009003283A (es) Inhibidores de la actividad de la akt
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
EA201690265A2 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2010002592A (es) Composicion farmaceutica topica para la combinacion de acido fusidico y corticoesteroides.
MX369385B (es) Productos para cicatrizar heridas tisulares.
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MF4A Revocation of a eurasian patent as invalid entirely

Designated state(s): RU